Fluidx Medical has released information regarding the success of the IMPASS Embolic Device in in vivo research related to middle meningeal artery (MMA) embolizations which can be used to treat chronic subdural haematomas (CSDH) on the surface of the brain.
CSDH is a common pathology that can result in death and/or disability in patients. The typical treatment of CSDH involves drilling a hole in the skull and draining the blood. Minimally invasive catheter-based MMA embolization can be an alternative to surgical treatment.
“We have been listening to clinicians and they need better tools to treat CSDH,” says Danny Smith, vice president of research and development for Fluidx. “We designed the IMPASS embolization device to work with standard embolization catheters and embolize microvasculature in the MMA. Our results are encouraging and the IMPASS product could be a great solution to unmet patient needs.”
MMA embolization is a promising option to address CSDH and is particularly appealing for elderly patients and others who cannot undergo invasive surgical procedures. Hundreds of thousands of patients with CSDHs may benefit from this minimally invasive procedure. During the procedure, a small catheter is navigated into the MMA located within the dura mater which covers the brain, then an embolic material is delivered into the vessel to block arterial flow.
The Fluidx embolic platform is expected to bring simple preparation and controllable material delivery to a range of applications. The IMPASS device is packaged in a ready-to-use syringe, can be prepped tableside by the clinician in about 30 seconds, and may be delivered through standard microcatheters (no complex mixing systems or special delivery catheters are necessary).